A Phase III AENEAS trial conducted in China revealed that for patients with advanced NSCLC harboring EGFR-sensitive mutations, Almonertinib extended median PFS to 19.3 months, compared to 9.9 months with gefitinib (19). Here, EGFR is linked to non-small cell lung carcinoma.